Molbio Diagnostics IPO
Molbio Diagnostics IPO is a mainboard IPO raising ₹940 Cr at ₹768 – ₹807 a share. It listed on 17 Aug 2026 at ₹980, +21.4% against its issue price of ₹807, and trades at ₹1,260 today (+56.1% since issue). It was subscribed 70× in total.
70.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
Where your money goes
Only the fresh issue reaches the company. The offer for sale is existing shareholders selling their own stock — that money goes to them, not the business.
79% of this issue is existing shareholders cashing out. Only ₹200 Cr reaches the business.
A red herring prospectus is filed before the price is fixed, so it states share counts rather than rupee amounts. derived: shares x cut-off price Rs807. Checked: exchange issue size Rs940 Cr vs derived Rs939.7 Cr (0.0% apart).
What the fresh money funds
The stated uses of the net proceeds, from the prospectus’s Objects of the Issue table. Only the fresh issue funds these — the offer-for-sale money goes to the selling shareholders above.
As stated in the prospectus — stated total ₹200 Cr. “General corporate purposes” is the part with no committed use; SEBI caps it at 25% of the issue.
The price they’re asking
From the prospectus’s own “Basis for Issue Price” — the issuer’s earnings multiple against the peers it chose to compare itself with.
Priced 13% below the median multiple of the peers the issuer itself names.
| Listed peer (issuer’s choice) | P/E | RoNW | EPS |
|---|---|---|---|
| Poly Medicure Limited | 52.61× | 10.37% | ₹31.75 |
| Dr. Lal Pathlabs Limited | 62.2× | 20.78% | ₹30.2 |
| Metropolis Healthcare Limited | 63.72× | 12.56% | ₹9.19 |
| Vijaya Diagnostics Centre Limited | 81.02× | 18.07% | ₹16.79 |
| This issue | 54.6× | 14.55% | ₹14.77 |
derived: cut-off price Rs807 / stated EPS Rs14.77 (FY2026 diluted EPS (year ended March 31, 2026), restated consolidated, after bonus issue adjustment). Peer figures are as printed in the prospectus — they date from its filing, not today. A multiple is one lens, not a verdict.
Terms of the issue
The mechanics of what is being sold. Held for every issue we track.
Not here yet
The anchor-investor allocation — which institutions were allotted shares before bidding opened — is still to be read out of its document.